VolitionRx Ltd. has announced a significant financial development by entering into a waiver agreement with Lind Global Asset Management. This agreement allows VolitionRx to make a partial prepayment of $500,000 on a senior secured convertible promissory note, easing immediate financial pressures on the company.

The waiver, effective October 23, 2026, includes terms that defer future monthly repayments for November and December 2026. This strategic move is aimed at providing VolitionRx with additional liquidity as it navigates its financial obligations.

Background

VolitionRx Ltd. is a company engaged in the development of in vitro diagnostic substances, primarily focusing on cancer detection and other medical diagnostics. The company trades under the ticker symbol VNRX on the NYSE American exchange. As a smaller reporting company, VolitionRx is categorized as a non-accelerated filer.

What the Filing Says

According to the recent SEC filing, VolitionRx and Lind Global Asset Management entered into a waiver agreement that stipulates:

“Lind agreed to accept a partial prepayment of outstanding principal by the Company in the amount of $500,000.”

Additionally, Lind has agreed not to exercise its conversion rights under the note until certain conditions are met, specifically if the closing price per share of Volition’s common stock equals or exceeds $0.275.

Impact

This agreement may significantly affect VolitionRx's financial strategy and operational flexibility. By allowing for a partial prepayment and deferring future repayment obligations, the company can manage its cash flow more effectively during a critical period. This move may also influence investor perceptions and confidence in the company's financial health.

What's Next

The filing does not say what happens next, but the company has indicated it will continue to work closely with Lind Global Asset Management regarding its financial obligations.